Fudan Zhangjiang released a report for the third quarter of 2021 that the company's operating income was 299 million yuan, up 14.77% from the same period last year. The net profit belonging to shareholders of listed companies was 53.1288 million yuan, down 4.73% from the same period last year; the net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 47.3208 million yuan, down 0.56% from the same period last year; and basic earnings per share was 0.05 yuan.

According to the third quarterly report of Fudan Zhangjiang 2021, the company's main income was 698 million yuan, up 40.69% from the same period last year; the net profit was 119 million yuan, up 39.8% from the same period last year; and the non-net profit was 102 million yuan, up 75.28% from the same period last year. Among them, in the third quarter of 2021, the company's main income in a single quarter was 299 million yuan, up 14.77% from the same period last year; the net profit in a single quarter was 53.1288 million yuan, down 4.73% from the same period last year The non-net profit in a single quarter was 47.3208 million yuan, down 0.56% from the same period last year; the debt ratio was 18.81%, the investment income was 10.1447 million yuan, the financial expenses were-3.8106 million yuan, and the gross profit margin was 92.97%.

The stock has no agency rating in the last 90 days. In the past three months, the net outflow of financing was 2.9977 million, and the financing balance decreased; the net outflow of securities was 2.9083 million, and the balance of securities lending decreased. According to the Securities Star valuation analysis tool, Fudan Zhangjiang (688505) good company has a rating of 3.5 stars, a good price rating of 1 star, and a comprehensive valuation rating of 2 stars.

The chairman of the company is Wang Haibo. Mr. Wang Haibo: born in October 1960, Chinese nationality, Hungarian permanent residence, master's degree, associate professor, was appointed as executive director, chairman and general manager of the board of directors in November 1996. At the same time, he is also the chairman of Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd., a subsidiary of the Company, and a director of Fengyi (Hong Kong) Holdings Limited. He founded the company in November 1996. He was an associate professor at Fudan University from May 1995 to June 1996. He has published a number of papers and has been awarded a number of awards, such as the third prize of the National Spark Award, the second prize of the Education Commission and the Shanghai Science and Technology Progress Award. He graduated from Fudan University and received a Bachelor's degree in Biology in July 1983 and a Master's degree in July 1986. He also served as the Technical Director of Zhejiang Shenghua Baike Biology Co., Ltd., a company listed on the Shanghai Stock Exchange (Shanghai Stock Exchange Stock Code: 600226).

This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.